Last reviewed · How we verify

NCT05582811

Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers

Completed NA Last updated 5 January 2024
What this trial tests

NA trial testing Dose Riociguat 2,5 or 5mg in Headache in 15 participants. Completed in 1 June 2023.

Timeline
26 October 2022
Primary endpoint
1 June 2023
1 June 2023

Quick facts

Lead sponsorDanish Headache Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposeother
Enrollment15
Start date26 October 2022
Primary completion1 June 2023
Estimated completion1 June 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Danish Headache Center — full company profile →

Who can join

Adults 18 to 45, any sex, with Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blind, randomized, placebo-controlled cross-over clinical trial aims to investigate the effects of riocigaut on cerebral arteries and headache inducing properties in healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Soluble guanylate cyclase induces cranial vasodilation and headache in adults: a randomized trial.
    Rasmussen NB, Christensen CE, Ashina H, Amin FM, et al · · 2025 · cited 1× · PMID 41322201 · DOI 10.1093/braincomms/fcaf436

Verify or expand the search:

Other recruiting trials for Headache

Currently open trials in the same condition.

Other Danish Headache Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05582811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing